Opinion: The local news crisis is also a public health crisis
Health and science reporting is often treated as optional coverage. It is anything but.
Medical News
Psychedelics get a boost from the White House
In this week’s STATus Report, host Alex Hogan chats with STAT Washington correspondent Daniel Payne about Trump's psychedelics EO.
Fierce Pharma Asia—Merck’s PD-1xVEGF data; Zai Lab’s global view; Kailera’s record IPO
Merck & Co. unveiled the much-anticipated first look at its PD-1xVEGF bispecific data. China's Zai Lab is looking to go global. With a pipeline licensed from Hengrui Pharma, Kailera Therapeutics pulled off a record IPO. And more.
Patients less confident than ever about health choices: survey
Patients’ confidence in their ability to find answers about health questions and make informed decisions has plummeted in the past year, according to an Edelman survey.
Pfizer drafts Fernando Mendoza as new face of its ‘game of inches’ cancer campaign
Pfizer is kicking off the next stage of its cancer awareness program by teaming up with quarterback Fernando Mendoza.
Avalyn aims for $182M IPO to fund phase 3 trials of reformulated respiratory drugs
Avalyn Pharma is hoping to rake in around $181.8 million from an IPO, which the biotech will use to take its inhaled versions of approved drugs for respiratory conditions into late-stage studies.
A CAR-T biotech’s dramatic turnaround, and drugmakers’ tactics to drive more scripts
This week on "The Readout LOUD": a CAR-T biotech's dramatic turnaround, and drugmakers' tactics to drive more scripts. Listen now.
STAT+: Trump celebrates closing first round of drug pricing deals, promises more ahead
A deal with Regeneron was the last of 17 initially sought by the White House.
Heart’s beat may help it beat cancer, mouse research suggests
The constant pressure that the heart is under from beating thousands of times a day may create an environment hostile to cancers
STAT+: Trump’s boosting of psychedelics, cannabis signal a new era in GOP drug policy
The Trump administration, in a stark departure from the "Just Say No" era, is funding psychedelics research and rescheduling marijuana.
Ancient mass grave reveals how a pandemic wiped out a city 1,500 years ago
A newly confirmed mass grave in ancient Jordan offers chilling insight into one of history’s first pandemics. Hundreds of plague victims were buried within days, revealing how the Plague of Justinian devastated entire communities. The findings show that people who usually lived spread out across regions were suddenly concentrated in death. It’s a powerful reminder that pandemics don’t just spread
STAT+: Legislatures in Colorado and Virginia resist moves to constrain drug affordability boards
Legislators in two states are resisting efforts to restrict prescription drug affordability boards.
Can Trump’s deal with the UK become a model for similar drug price agreements?
Trump’s deal with the UK links tariffs to drug pricing. On this week’s "The Top Line," we examine whether similar agreements could follow.
Opinion: Dropping the flu vaccine requirement puts U.S. military readiness at risk
Since the 1918 pandemic, the military has acknowledged the threat of influenza. Now that’s changing.
STAT+: Sanofi research priorities in flux as new CEO logs in
A gene therapy for deafness, all eyes on Erasca, and other biotech news from The Readout
Regeneron ushers in new genetic medicine era with groundbreaking gene therapy approval
Travis Smith was a very serious baby. Born completely unable to hear, his mother Sierra struggled to see his personality shine through his mute world.
Regeneron to unveil latest 'most favored nation' drug pricing deal with White House
With Regeneron poised to announce a drug pricing deal with the White House Thursday, all 17 companies targeted in a round of letters by the Trump administration last year have agreed to play ball with the President’s “most favored nation” strategy.
Despite data concerns, Roche’s oral SERD can still be largest product in company history: exec
While the scale of the currency headwinds in Roche’s first-quarter financial update caught many off guard, the company’s earnings call still featured much discussion on a pivotal pipeline prospect: the oral SERD drug giredestrant. The drug carries blockbuster ambitions, yet its commercial path has been clouded by imperfect clinical data.
Roche Q1 earnings suffer blood bath, but currency headwinds aren’t the only culprit
In a brutal first quarter for Roche, key drugs in the company’s pharmaceutical division fall short of Wall Street expectations—big time. But the surging Swiss franc is only one piece of some disappointing sales figures.
FDA citizen petition calls on agency to tighten up CRL disclosure practices
The citizen petition takes issue with the FDA's new practice of publicly releasing batches of complete response letters in response to unapproved drug applications.